Analyst Price Target is $45.40
▲ +53.38% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $45.40, with a high forecast of $79.00 and a low forecast of $15.00. The average price target represents a 53.38% upside from the last price of $29.60.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in TransMedics Group. This Buy consensus rating has held steady for over two years.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.